IQUIX Launched at the 2007 AAO Meeting: Review of Santen’s Portfolio
Adrienne Graves PhD, President and CEO of Santen, highlights their product portfolio from dry eye to retina and glaucoma (Alamast, Quixin, and Betimol). She is interviewed by Dr. Andrew Moshfeghi, Associate Retina Editor for OphthalmologyWeb, and Dr. David Goldman, Refractive Editor for OphthalmologyWeb. She discusses the launch of IQUIX (1.5% levofloxacin) at this year's AAO meeting in New Orleans. IQUIX is BAK-free, and has a much reduced dosing regimen compared to the other fluoroquinolones approved for corneal ulcer. Their novel rho-kinase (ROCK) inhibitor for the treatment of glaucoma is in (Read more...)